The listing below shows our latest News Items and is updated regularly. If you wish to post a news item please select the 'Post News' button on the right. The displayed news feed starts on 1st August 2016. Older items can be found here.
To 'Post Your News' use the button at the top right.
We are pleased to present below all posts archived in 'December 2020'. If you still can't find what you are looking for, try using the search box.
Yourgene, the international molecular diagnostics group, announces that Yourgene Genomic Services has been added to the UK Government’s approved COVID-19 private testing providers list for the Test to Release for International Travel scheme introduced on 15 December 2020 (“Test to Release”), and also for general coronavirus testing. The Company has also conducted in silico analysis studies into the effect of the new virus strain which suggests that the performance of its test will be unaffected.
Read the rest of entry »
LSBio , a leading provider of antibodies and life science research reagents, is pleased to announce its acquisition of Redcar, UK-based Absolute Antibody, Ltd. and its sister company Kerafast. Terms of the transaction were not disclosed
We recently invited four experts in IP, Employment, Regulatory and Grant Funding to tell us what we can expect from the end of the Brexit Transition and have summarised the points here for your easy reference.
AMSBIO offer a wide range of Heparan Sulfate antibodies, enzymes, standards and ready-to-use Heparanase activity assays for researchers seeking to better understand COVID-19 and thereby to combat the pandemic.
Arctoris Ltd, an Oxford-based research company operating a fully automated drug discovery platform, has appointed three distinguished experts as members of its Advisory Board: Beth J Hoffman PhD, Professor Khusru Asadullah MD, and Stanley Lapidus.
ONA Therapeutics, Absolute Antibody and RIC - three leading European companies in the biotech landscape - have been awarded a Eurostars grant for a two-year project that will develop a proprietary biological drug with a unique mode of action for the treatment of various types of metastatic cancers
AMSBIO reports how the internationally renowned Hans Clevers Lab at the Hubrecht Institute, Netherlands used their CELLBANKER® reagent when they needed to freeze down their organoids at short notice ahead of the COVID-19 spring lockdown.
Arecor Ltd, the biopharmaceutical company advancing today’s therapies to enable healthier lives, today announces that its partner, Inhibrx, Inc., has exercised an option to license a novel enhanced formulation of Inhibrx’s proprietary therapeutic candidate, INBRX-101, developed by Arecor using the Company’s patented technology, Arestat™. This is the first license under a multi-product development agreement between Inhibrx and Arecor.
OBN aims to provide sector NEWS that is relevant to our Membership. We filter information from a variety of sources, publish items ourselves and will publish items of News from our Members. Press releases about OBN can be found here.